Your browser doesn't support javascript.
Antibody binding and neutralization of live SARS-CoV-2 variants including BA.4/5 following booster vaccination of patients with B-cell malignancies.
Chang, Andres; Akhtar, Akil; Lai, Lilin; Orellana-Noia, Victor M; Linderman, Susanne L; McCook-Veal, Ashley A; Switchenko, Jeffrey M; Saini, Manpreet; Valanparambil, Rajesh M; Blum, Kristie A; Allen, Pamela B; Lechowicz, Mary Jo; Romancik, Jason T; Ayers, Amy; Leal, Alyssa; O'Leary, Colin B; Churnetski, Michael C; Baird, Katelin; Kives, Melissa; Wrammert, Jens; Nooka, Ajay K; Koff, Jean L; Dhodapkar, Madhav V; Suthar, Mehul S; Cohen, Jonathon B; Ahmed, Rafi.
  • Chang A; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Akhtar A; Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.
  • Lai L; Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.
  • Orellana-Noia VM; Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.
  • Linderman SL; Department of Pediatrics, Emory University Schools of Medicine, Atlanta, GA.
  • McCook-Veal AA; Emory National Primate Research Center, Atlanta, GA.
  • Switchenko JM; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Saini M; Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.
  • Valanparambil RM; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
  • Blum KA; Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, GA, USA.
  • Allen PB; Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.
  • Lechowicz MJ; International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi, India.
  • Romancik JT; Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.
  • Ayers A; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Leal A; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • O'Leary CB; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Churnetski MC; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Baird K; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Kives M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wrammert J; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Nooka AK; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Koff JL; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Dhodapkar MV; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Suthar MS; Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322.
  • Cohen JB; Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.
  • Ahmed R; Department of Pediatrics, Emory University Schools of Medicine, Atlanta, GA.
Cancer Res Commun ; 2(12): 1684-1692, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-2194265
ABSTRACT
Non-Hodgkin lymphoma and chronic lymphocytic leukemia (NHL/CLL) patients elicit inadequate antibody responses after initial SARS-CoV-2 vaccination and remain at high risk of severe COVID-19 disease. We investigated IgG, IgA, and IgM responses after booster vaccination against recent SARS-CoV-2 variants including Omicron BA.5 in 67 patients. Patients had lower fold increase and total anti-spike binding titers after booster than healthy individuals. Antibody responses negatively correlated with recent anti-CD20 therapy and low B cell numbers. Antibodies generated after booster demonstrated similar binding properties against SARS-CoV-2 variants compared to those generated by healthy controls with lower binding against Omicron variants. Importantly, 43% of patients showed anti-Omicron BA.1 neutralizing antibodies after booster and all these patients also had anti-Omicron BA.5 neutralizing antibodies. NHL/CLL patients demonstrated inferior antibody responses after booster vaccination, particularly against Omicron variants. Prioritization of prophylactic and treatment agents and vaccination of patients and close contacts with updated vaccine formulations are essential.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Journal: Cancer Res Commun Year: 2022 Document Type: Article

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Topics: Vaccines / Variants Language: English Journal: Cancer Res Commun Year: 2022 Document Type: Article